A Pilot Study of the Safety, Efficacy, and Effects on Functional Imaging of the Combination of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Girentuximab (Primary) ; Sunitinib (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Registrational
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG
- 27 Feb 2013 Last checked against ClinicalTrials.gov record.
- 01 Sep 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.